Nifty
Sensex
:
:
11971.60
39773.53
233.70 (1.99%)
663.32 (1.70%)

Pharmaceuticals & Drugs

Rating :
63/99

BSE: 500420 | NSE: TORNTPHARM

1554.40
-5.10 (-0.33%)
23-May-2019 | 10:54AM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  1561.00
  •  1580.35
  •  1541.85
  •  1559.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  96276
  •  1496.51
  •  1962.00
  •  1303.55

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 26,383.02
  • 60.51
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 31,978.08
  • 0.90%
  • 5.59

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 71.25%
  • 2.42%
  • 6.79%
  • FII
  • DII
  • Others
  • 0.15%
  • 9.55%
  • 9.84%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.88
  • 7.41
  • -3.64

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.89
  • 7.10
  • -13.25

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.91
  • 0.43
  • -26.86

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.69
  • 22.01
  • 27.05

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.58
  • 6.28
  • 5.66

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 12.51
  • 14.15
  • 15.22

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Net Sales
1,856.00
1,722.00
7.78%
2,051.00
1,463.00
40.19%
1,894.00
1,417.00
33.66%
1,872.00
1,362.00
37.44%
Expenses
1,383.00
1,358.00
1.84%
1,490.00
1,104.00
34.96%
1,421.00
1,088.00
30.61%
1,395.00
1,065.00
30.99%
EBITDA
473.00
364.00
29.95%
561.00
359.00
56.27%
473.00
329.00
43.77%
477.00
297.00
60.61%
EBIDTM
25.48%
21.14%
27.35%
24.54%
24.97%
23.22%
25.48%
21.81%
Other Income
17.00
42.00
-59.52%
3.00
74.00
-95.95%
10.00
78.00
-87.18%
27.00
105.00
-74.29%
Interest
123.00
121.00
1.65%
133.00
80.00
66.25%
126.00
51.00
147.06%
122.00
56.00
117.86%
Depreciation
160.00
151.00
5.96%
156.00
94.00
65.96%
152.00
84.00
80.95%
150.00
80.00
87.50%
PBT
-150.00
134.00
-
275.00
259.00
6.18%
205.00
272.00
-24.63%
232.00
266.00
-12.78%
Tax
2.00
-94.00
-
29.00
201.00
-85.57%
26.00
68.00
-61.76%
69.00
78.00
-11.54%
PAT
-152.00
228.00
-
246.00
58.00
324.14%
179.00
204.00
-12.25%
163.00
188.00
-13.30%
PATM
-8.19%
13.24%
11.99%
3.96%
9.45%
14.40%
8.71%
13.80%
EPS
-8.98
13.47
-
14.54
3.43
323.91%
10.58
12.05
-12.20%
9.63
11.11
-13.32%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
7,673.00
5,982.26
5,815.69
6,686.93
4,653.45
4,184.72
3,211.14
2,695.92
2,197.79
1,916.04
1,630.66
Net Sales Growth
28.66%
2.86%
-13.03%
43.70%
11.20%
30.32%
19.11%
22.67%
14.70%
17.50%
 
Cost Of Goods Sold
2,219.00
1,535.17
1,629.66
1,452.21
1,280.96
1,107.58
807.98
774.38
616.64
516.71
487.56
Gross Profit
5,454.00
4,447.09
4,186.03
5,234.72
3,372.49
3,077.14
2,403.16
1,921.54
1,581.16
1,399.32
1,143.10
GP Margin
71.08%
74.34%
71.98%
78.28%
72.47%
73.53%
74.84%
71.28%
71.94%
73.03%
70.10%
Total Expenditure
5,689.00
4,641.21
4,438.42
3,957.13
3,633.29
3,233.24
2,518.92
2,203.54
1,810.01
1,495.26
1,371.93
Power & Fuel Cost
-
118.77
107.98
92.59
97.41
71.88
62.80
56.97
42.53
27.40
25.29
% Of Sales
-
1.99%
1.86%
1.38%
2.09%
1.72%
1.96%
2.11%
1.94%
1.43%
1.55%
Employee Cost
-
1,135.25
993.41
842.35
841.81
741.10
623.29
531.80
440.44
308.33
250.38
% Of Sales
-
18.98%
17.08%
12.60%
18.09%
17.71%
19.41%
19.73%
20.04%
16.09%
15.35%
Manufacturing Exp.
-
457.58
502.16
353.45
345.98
320.78
278.15
225.27
210.89
223.19
200.42
% Of Sales
-
7.65%
8.63%
5.29%
7.43%
7.67%
8.66%
8.36%
9.60%
11.65%
12.29%
General & Admin Exp.
-
718.38
578.05
637.92
477.59
399.07
324.55
255.89
206.88
177.67
150.91
% Of Sales
-
12.01%
9.94%
9.54%
10.26%
9.54%
10.11%
9.49%
9.41%
9.27%
9.25%
Selling & Distn. Exp.
-
633.06
567.70
547.05
574.40
461.53
393.07
322.29
274.61
225.10
197.36
% Of Sales
-
10.58%
9.76%
8.18%
12.34%
11.03%
12.24%
11.95%
12.49%
11.75%
12.10%
Miscellaneous Exp.
-
43.00
59.46
31.56
15.14
131.30
29.08
36.94
18.03
16.85
197.36
% Of Sales
-
0.72%
1.02%
0.47%
0.33%
3.14%
0.91%
1.37%
0.82%
0.88%
3.68%
EBITDA
1,984.00
1,341.05
1,377.27
2,729.80
1,020.16
951.48
692.22
492.38
387.78
420.78
258.73
EBITDA Margin
25.86%
22.42%
23.68%
40.82%
21.92%
22.74%
21.56%
18.26%
17.64%
21.96%
15.87%
Other Income
57.00
307.04
223.30
228.80
285.55
38.13
43.36
52.78
56.23
21.63
23.79
Interest
504.00
308.48
205.56
183.98
175.16
58.63
33.80
39.45
39.13
29.10
39.30
Depreciation
618.00
408.60
306.92
237.55
190.74
87.00
82.69
81.73
62.56
66.09
42.28
PBT
562.00
931.01
1,088.09
2,537.07
939.81
843.98
619.09
423.98
342.33
347.22
200.95
Tax
126.00
252.87
154.51
610.17
188.84
180.07
146.69
72.32
72.17
116.02
7.82
Tax Rate
22.42%
27.16%
14.20%
26.04%
20.09%
21.34%
25.22%
20.17%
21.08%
33.41%
4.07%
PAT
436.00
678.11
933.55
1,733.24
750.94
663.88
432.76
284.04
270.17
231.20
184.37
PAT before Minority Interest
436.00
678.14
933.58
1,733.27
750.97
663.91
434.91
286.30
270.17
231.20
184.37
Minority Interest
0.00
-0.03
-0.03
-0.03
-0.03
-0.03
-2.15
-2.26
0.00
0.00
0.00
PAT Margin
5.68%
11.34%
16.05%
25.92%
16.14%
15.86%
13.48%
10.54%
12.29%
12.07%
11.31%
PAT Growth
-35.69%
-27.36%
-46.14%
130.81%
13.11%
53.41%
52.36%
5.13%
16.86%
25.40%
 
Unadjusted EPS
25.77
40.07
55.17
102.42
44.38
39.23
25.58
33.57
31.93
27.32
21.79

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
4,622.19
4,350.13
3,494.10
2,490.56
1,902.43
1,421.93
1,193.83
1,022.40
830.98
650.89
Share Capital
84.62
84.62
84.62
84.62
84.62
42.31
42.31
42.31
42.31
42.31
Total Reserves
4,537.57
4,265.51
3,409.48
2,405.94
1,817.81
1,379.62
1,151.52
980.10
788.67
608.58
Non-Current Liabilities
4,142.42
2,303.33
1,994.65
2,504.92
926.76
619.81
487.73
397.60
572.29
541.00
Secured Loans
4,105.31
2,229.57
1,839.46
2,171.60
730.72
403.19
223.83
170.59
364.64
318.27
Unsecured Loans
6.15
11.26
10.62
13.62
13.74
51.35
98.22
122.45
157.75
164.33
Long Term Provisions
286.66
263.04
246.36
207.49
190.43
129.51
110.45
56.14
0.00
0.00
Current Liabilities
5,202.17
2,738.26
3,285.48
2,823.75
2,174.58
1,710.65
1,362.84
1,114.09
549.59
465.64
Trade Payables
2,048.24
1,749.32
2,260.22
1,827.72
1,429.13
1,067.74
863.47
615.00
383.60
313.41
Other Current Liabilities
1,151.68
687.14
822.28
446.15
371.63
275.83
291.00
312.85
43.39
60.90
Short Term Borrowings
1,625.60
0.00
3.32
319.07
210.43
124.62
138.12
99.57
0.00
0.00
Short Term Provisions
376.65
301.80
199.66
230.81
163.39
242.46
70.25
86.66
122.60
91.33
Total Liabilities
13,967.30
9,392.21
8,774.69
7,819.66
5,004.17
3,752.76
3,047.90
2,535.69
1,952.86
1,657.53
Net Block
7,854.68
3,688.44
2,859.08
2,832.66
875.34
819.82
796.87
635.55
541.15
511.25
Gross Block
9,449.48
4,909.80
3,793.53
3,542.93
1,420.04
1,278.15
1,199.64
964.28
812.94
720.62
Accumulated Depreciation
1,594.80
1,221.36
934.45
710.27
544.70
458.33
402.77
328.73
271.79
209.37
Non Current Assets
8,704.89
4,512.74
4,085.66
3,768.25
1,599.69
1,191.87
1,060.78
941.27
670.02
583.72
Capital Work in Progress
646.94
519.49
1,041.58
678.33
534.11
285.28
113.55
179.88
109.82
53.42
Non Current Investment
0.09
0.09
0.09
0.06
0.03
0.03
37.52
20.00
19.05
19.05
Long Term Loans & Adv.
149.44
182.32
99.66
206.92
129.47
62.84
61.37
59.51
0.00
0.00
Other Non Current Assets
53.74
122.40
85.25
50.28
60.74
23.90
46.25
46.34
0.00
0.00
Current Assets
5,262.41
4,879.47
4,689.03
4,051.41
3,404.48
2,560.89
1,987.12
1,594.42
1,282.84
1,073.81
Current Investments
492.27
803.55
779.59
297.59
185.63
60.44
86.52
125.99
122.13
120.44
Inventories
1,966.30
1,559.15
1,357.98
1,067.17
1,006.06
923.86
531.56
504.83
323.63
264.54
Sundry Debtors
1,253.45
950.89
1,445.09
1,587.26
1,099.42
687.82
522.80
340.40
298.16
266.58
Cash & Bank
867.26
893.72
647.03
567.36
769.42
626.97
674.28
478.80
388.33
229.99
Other Current Assets
683.13
589.54
369.16
422.94
343.95
261.80
171.96
144.41
150.60
192.26
Short Term Loans & Adv.
96.24
82.62
90.18
109.09
84.95
75.95
56.46
49.28
109.06
157.94
Net Current Assets
60.24
2,141.21
1,403.55
1,227.66
1,229.90
850.24
624.28
480.33
733.26
608.17
Total Assets
13,967.30
9,392.21
8,774.69
7,819.66
5,004.17
3,752.76
3,047.90
2,535.69
1,952.86
1,657.53

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
894.18
1,008.84
2,742.12
810.20
599.42
153.48
499.13
395.01
287.00
257.90
PBT
931.01
1,088.09
2,343.44
939.81
843.98
581.60
358.62
342.33
347.22
192.19
Adjustment
606.92
430.27
552.44
337.96
136.79
126.13
79.64
74.80
80.63
82.04
Changes in Working Capital
-360.13
-125.21
423.58
-409.38
-119.68
-421.75
143.58
61.88
-74.82
10.12
Cash after chg. in Working capital
1,177.80
1,393.15
3,319.46
868.39
861.09
285.98
581.84
479.01
353.04
284.34
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-283.62
-384.31
-577.34
-58.19
-261.67
-132.50
-82.71
-84.00
-66.04
-26.44
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-4,706.95
-786.91
-837.85
-2,162.30
-355.81
-241.70
-136.97
-232.60
-128.71
-39.58
Net Fixed Assets
-4,245.22
-592.01
-471.42
-2,266.57
-308.01
-455.28
-84.67
-52.13
-152.17
-34.10
Net Investments
310.79
-17.69
-484.32
-111.97
-131.60
287.55
-47.29
-199.04
13.48
-86.91
Others
-772.52
-177.21
117.89
216.24
83.80
-73.97
-5.01
18.57
9.98
81.43
Cash from Financing Activity
3,417.39
-192.91
-1,435.15
1,212.25
86.40
19.73
-192.74
-67.61
-5.25
-18.23
Net Cash Inflow / Outflow
-395.38
29.02
469.12
-139.85
330.01
-68.49
169.42
94.80
153.05
200.09
Opening Cash & Equivalents
1,067.57
1,049.86
612.38
955.05
687.41
760.80
604.79
510.45
350.43
153.84
Closing Cash & Equivalent
702.07
1,067.57
1,049.86
864.95
955.05
687.41
760.80
604.79
510.45
350.43

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
273.11
257.04
206.46
147.16
112.41
84.02
70.54
60.42
49.11
38.46
ROA
5.81%
10.28%
20.89%
11.71%
15.16%
12.79%
10.26%
12.04%
12.81%
12.61%
ROE
15.12%
23.80%
57.92%
34.19%
39.94%
33.25%
25.84%
29.15%
31.20%
31.78%
ROCE
13.81%
20.36%
45.63%
26.98%
35.06%
31.66%
23.65%
25.88%
30.26%
23.12%
Fixed Asset Turnover
0.84
1.35
1.82
1.88
3.11
2.60
2.50
2.48
2.54
2.43
Receivable days
67.03
74.66
82.76
105.19
77.81
68.65
58.33
52.95
52.84
52.49
Inventory Days
107.20
90.90
66.19
81.17
84.02
82.53
70.03
68.69
55.03
54.44
Payable days
151.26
171.27
204.35
176.11
158.58
143.69
136.22
103.96
90.60
83.99
Cash Conversion Cycle
22.96
-5.72
-55.41
10.25
3.25
7.50
-7.86
17.68
17.27
22.94
Total Debt/Equity
1.40
0.58
0.67
1.10
0.59
0.49
0.48
0.56
0.63
0.74
Interest Cover
4.02
6.29
13.74
6.37
15.40
18.21
10.09
9.75
12.93
5.89

News Update:


  • Torrent Pharmaceuticals reports consolidated net loss of Rs 152 crore in Q4
    21st May 2019, 11:43 AM

    Total consolidated income of the company rose by 7.03% at Rs 1,873.00 crore for quarter ended March 31, 2019

    Read More
  • Torrent Pharmaceuticals raises Rs 100 crore via CPs
    20th May 2019, 09:17 AM

    The tenure of the instrument is 129 days and will mature on September 23, 2019

    Read More
  • Torrent Pharma initiates recalls of over 8 lakh bottles of Losartan Potassium tablets
    13th May 2019, 11:21 AM

    All the ongoing voluntary recalls of the hypertension treatment drug are class II recalls

    Read More
  • Torrent Pharmaceuticals raises Rs 200 crore via CPs
    6th May 2019, 10:25 AM

    ICRA has granted rating of ‘A1 +’ for issuance of Commercial papers by the company

    Read More
  • Torrent Pharmaceuticals gets observations from USFDA for Indrad plant
    26th Apr 2019, 10:38 AM

    The audit at Indrad Plant of the company was carried out by USFDA in the month of April, 2019

    Read More
  • Torrent Pharma’s arm recalls over 10.78 lakh bottles of hypertension tablets from US
    22nd Apr 2019, 12:54 PM

    The reason for the recalls is presence of an impurity in the finished product above the interim acceptable daily intake level of 9.82 per million

    Read More
  • Torrent Pharmaceuticals gets observations from USFDA for Dahej plant
    8th Apr 2019, 11:38 AM

    The audit at Dahej Plant of the company was carried out by USFDA in the month of March, 2019

    Read More
  • Torrent Pharma recalls 2.30 lakh bottles of high BP treatment tablets from US
    1st Mar 2019, 10:35 AM

    The tablets were manufactured by Torrent Pharma in its Mehsana facility in India

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.